In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci - PubMed (original) (raw)

In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci

R S Schwalbe et al. Antimicrob Agents Chemother. 1996 Oct.

Abstract

The in vitro activities of LY333328 were compared with those of vancomycin, teicoplanin, and quinupristin-dalfopristin (Synercid) against 219 strains of enterococci and staphylococci, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. MICs and MBCs were determined by a microtiter dilution protocol. LY333328 demonstrated superior activity against vancomycin-resistant enterococci and was the only antibiotic which was bactericidal. Its potency was comparable or superior to those of other antibiotics tested against methicillin-resistant staphylococci.

PubMed Disclaimer

Comment in

• Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
  Zelenitsky SA, Karlowsky JA, Zhanel GG, Hoban DJ, Nicas T. Zelenitsky SA, et al. Antimicrob Agents Chemother. 1997 Jun;41(6):1407-8. doi: 10.1128/AAC.41.6.1407. Antimicrob Agents Chemother. 1997. PMID: 9174212 Free PMC article. No abstract available.

Similar articles

• Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
  Harland S, Tebbs SE, Elliott TS. Harland S, et al. J Antimicrob Chemother. 1998 Feb;41(2):273-6. doi: 10.1093/jac/41.2.273. J Antimicrob Chemother. 1998. PMID: 9533471
• In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
  Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. Biavasco F, et al. Antimicrob Agents Chemother. 1997 Oct;41(10):2165-72. doi: 10.1128/AAC.41.10.2165. Antimicrob Agents Chemother. 1997. PMID: 9333042 Free PMC article.
• Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
  Fraise AP, Andrews J, Wise R. Fraise AP, et al. J Antimicrob Chemother. 1997 Sep;40(3):423-5. doi: 10.1093/jac/40.3.423. J Antimicrob Chemother. 1997. PMID: 9338497
• Glycopeptide derivatives.
  Malabarba A, Ciabatti R. Malabarba A, et al. Curr Med Chem. 2001 Dec;8(14):1759-73. doi: 10.2174/0929867013371716. Curr Med Chem. 2001. PMID: 11562292 Review.
• Glycopeptide antibiotics: from conventional molecules to new derivatives.
  Van Bambeke F, Van Laethem Y, Courvalin P, Tulkens PM. Van Bambeke F, et al. Drugs. 2004;64(9):913-36. doi: 10.2165/00003495-200464090-00001. Drugs. 2004. PMID: 15101783 Review.

Cited by

• Oritavancin for acute bacterial skin and skin structure infections.
  Messina JA, Fowler VG Jr, Corey GR. Messina JA, et al. Expert Opin Pharmacother. 2015 May;16(7):1091-8. doi: 10.1517/14656566.2015.1026256. Epub 2015 Mar 24. Expert Opin Pharmacother. 2015. PMID: 25803197 Free PMC article. Review.
• Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
  Arias CA, Mendes RE, Stilwell MG, Jones RN, Murray BE. Arias CA, et al. Clin Infect Dis. 2012 Apr;54 Suppl 3(Suppl 3):S233-8. doi: 10.1093/cid/cir924. Clin Infect Dis. 2012. PMID: 22431854 Free PMC article.
• Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.
  Higgins DL, Chang R, Debabov DV, Leung J, Wu T, Krause KM, Sandvik E, Hubbard JM, Kaniga K, Schmidt DE Jr, Gao Q, Cass RT, Karr DE, Benton BM, Humphrey PP. Higgins DL, et al. Antimicrob Agents Chemother. 2005 Mar;49(3):1127-34. doi: 10.1128/AAC.49.3.1127-1134.2005. Antimicrob Agents Chemother. 2005. PMID: 15728913 Free PMC article.
• Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.
  Cabellos C, Fernàndez A, Maiques JM, Tubau F, Ardanuy C, Viladrich PF, Liñares J, Gudiol F. Cabellos C, et al. Antimicrob Agents Chemother. 2003 Jun;47(6):1907-11. doi: 10.1128/AAC.47.6.1907-1911.2003. Antimicrob Agents Chemother. 2003. PMID: 12760866 Free PMC article.
• Therapeutic compounds targeting Lipid II for antibacterial purposes.
  Malin JJ, de Leeuw E. Malin JJ, et al. Infect Drug Resist. 2019 Aug 23;12:2613-2625. doi: 10.2147/IDR.S215070. eCollection 2019. Infect Drug Resist. 2019. PMID: 31692545 Free PMC article.

References

1. 1. J Antimicrob Chemother. 1992 Jul;30 Suppl A:45-51 - PubMed
2. 1. Antimicrob Agents Chemother. 1989 Apr;33(4):585-8 - PubMed
3. 1. Antimicrob Agents Chemother. 1989 Jul;33(7):995-9 - PubMed
4. 1. J Infect Dis. 1990 Jan;161(1):45-51 - PubMed
5. 1. Am J Med. 1991 Sep 16;91(3B):72S-75S - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Europe PubMed Central
  • PubMed Central

• Medical

  • MedlinePlus Health Information